OWINGS MILLS, Md. & BEDFORD, Mass.--(BUSINESS WIRE)--National Neurovision Research Institute (NNRI), a research support organization for the Foundation Fighting Blindness and the leading non-government funding source for inherited orphan retinal degeneration research, and Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of novel resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration (AMD).
